Acrivon Therapeutics Inc (ACRV)

Jul 02, 2026

ACRVAcrivon Therapeutics Inc Options - Finviz

Jul 02, 2026

Jul 02, 2026

ACRIVON THERAPEUTICS INC (ACRV) Stock Price & Overview - ChartMill

Jul 02, 2026

Jun 27, 2026

Price to book forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView

Jun 27, 2026

Jun 26, 2026

Price to sales forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView

Jun 26, 2026

Jun 26, 2026

Acrivon Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRV) - TradingView

Jun 26, 2026

Jun 25, 2026

ACRV Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 25, 2026

Acrivon Therapeutics (ACRV) Slips 2.47% in Low-Volume Trade, Testing Key Support at $1.5Sector ETF Flow - dars.gov.et

Jun 25, 2026

Jun 22, 2026

Form 4 Acrivon Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa

Jun 22, 2026

Jun 22, 2026

Director-linked RA Capital funds receive 20,275 Acrivon (ACRV) stock options at $1.52 - Stock Titan

Jun 22, 2026

Jun 22, 2026

Acrivon (NASDAQ: ACRV) director granted 20,275 stock options at $1.52 - Stock Titan

Jun 22, 2026

Jun 22, 2026

Acrivon Therapeutics (ACRV) director Sharon Shacham awarded 20,275 stock options - Stock Titan

Jun 22, 2026

Jun 22, 2026

Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 strike - Stock Titan

Jun 22, 2026

Jun 22, 2026

Acrivon Therapeutics (ACRV) director granted options on 20,275 shares - Stock Titan

Jun 22, 2026

Jun 22, 2026

Acrivon Therapeutics (ACRV) director awarded 20,275-share option for RA Capital funds - Stock Titan

Jun 22, 2026

Jun 22, 2026

Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 - Stock Titan

Jun 22, 2026

Jun 18, 2026

Acrivon Shareholders Approve Expanded Equity Plan and Directors - The Globe and Mail

Jun 18, 2026

Jun 17, 2026

Acrivon Therapeutics Stockholders Approve Amended 2022 Equity Incentive Plan and Elect New Directors – June 2026 - Minichart

Jun 17, 2026

Jun 17, 2026

Acrivon Therapeutics shareholders approve equity plan changes and director elections - Investing.com UK

Jun 17, 2026

Jun 17, 2026

Acrivon Therapeutics shareholders approve equity plan changes and director elections By Investing.com - Investing.com India

Jun 17, 2026

Jun 17, 2026

Acrivon amends equity plan, shareholders approve 3,000,000-share increase - TradingView

Jun 17, 2026

Jun 17, 2026

Acrivon Therapeutics (ACRV) shareholders approve larger equity plan and elect directors - Stock Titan

Jun 17, 2026

Jun 17, 2026

Acrivon Therapeutics Inc (ACRV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026

Jun 17, 2026

Acrivon Therapeutics Inc (ACRV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026

Jun 17, 2026

Acrivon Therapeutics Inc (ACRV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026

Jun 17, 2026

Acrivon Therapeutics Inc (ACRV) Institutional Confidence - TradingKey

Jun 17, 2026

Jun 17, 2026

Acrivon Therapeutics Inc (ACRV) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 17, 2026

Jun 17, 2026

Acrivon Therapeutics Inc (ACRV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026

Jun 17, 2026

Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026

Jun 17, 2026

Acrivon Therapeutics Inc (ACRV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026

Jun 15, 2026

Gabelli Initiates Acrivon Therapeutics(ACRV.US) With Buy Rating, Announces Target Price $8 - Moomoo

Jun 15, 2026

Jun 15, 2026

Oppenheimer Initiates Acrivon Therapeutics(ACRV.US) With Buy Rating, Announces Target Price $8 - Moomoo

Jun 15, 2026

Jun 14, 2026

Acrivon Therapeutics (ACRV) Shows Modest Upside Amidst Key Technical LevelsDealer Delta - newsline.com

Jun 14, 2026

Jun 07, 2026

Acrivon Therapeutics (ACRV) Faces Continued Pressure, Testing Key Support After 7.7% DeclinePercent Above MA - newsline.com

Jun 07, 2026

Jun 05, 2026

Acrivon Therapeutics (ACRV) Slides 7.7% as Support Test Looms After Bearish MomentumDealer Positioning - newsline.com

Jun 05, 2026

Jun 04, 2026

ACRV Q1 2026 Earnings: EPS Beats Estimates as Clinical Pipeline AdvancesEPS Estimate Trend - newsline.com

Jun 04, 2026

May 31, 2026

ACRV Q1 2026 Earnings: Positive EPS Surprise Amid Pre-Revenue Pipeline ProgressEarnings Acceleration Picks - newsline.com

May 31, 2026

May 29, 2026

Acrivon Therapeutics (ACRV) Slides 1.23% as Stock Tests Key Support at $1.53Pairs Trade - The Legal Advocate

May 29, 2026

May 27, 2026

Acrivon Therapeutics Q1 2026 Earnings: Narrower Loss Per Share as Pipeline Progress ContinuesSurprise Factor Analysis - The Legal Advocate

May 27, 2026

May 27, 2026

Acrivon Therapeutics (ACRV) Edges Higher: Biotech Stock Tests Key Resistance at $1.77Double EMA - newsline.com

May 27, 2026

May 26, 2026

Acrivon (ACRV) CEO and EVP report RSU-related tax withholding move - Stock Titan

May 26, 2026

May 26, 2026

Acrivon Therapeutics (ACRV) Slides 1.71% as Stock Nears Critical Support ZoneDollar Neutral Pair - The Legal Advocate

May 26, 2026

May 23, 2026

Acrivon Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineDividend Increase Stocks - newsline.com

May 23, 2026

May 21, 2026

Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com UK

May 21, 2026

May 21, 2026

Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline By Investing.com - Investing.com Australia

May 21, 2026

May 21, 2026

Acrivon Therapeutics CEO to Participate in Virtual Fireside Chat at TD Cowen’s 7th Annual Oncology Innovation Summit - Quiver Quantitative

May 21, 2026

May 21, 2026

Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - The Manila Times

May 21, 2026